#Ocaliva

First Large Study Shows Liver Fibrosis Improvement in People with NASH

An FDA advisory committee expressed concerns about the safety of the fatty liver disease treatment.

The link between COVID-19 and liver disease, along with research about NAFLD and NASH, topped the Hep treatment news this year.

Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.

Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.

About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.

The application is based on study results showing that up to 23% of treated patients saw an improvement in liver fibrosis.

A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...

The FDA has approved Intercept Pharmaceuticals’ Ocaliva to treat primary biliary cholangitis, previously known as primary biliary cirrhosis.

The drug has been shown to help reduce markers of liver inflammation and fibrosis, as well as increase insulin sensitivity.